ReviewEuropean journal of clinical pharmacology2024
Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.
Review in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Mechanism of and research progress on alterations in the RET gene in thyroid cancer (Review).Molecular medicine reports · 2026Review
- Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.Journal of endocrinological investigation · 2026Observational
- Progressive Destructive Hypothyroidism Associated with Sunitinib Therapy: A Three-Year Case Analysis.Journal of clinical medicine · 2026Article
- Mild Primary Adrenal Insufficiency During Treatment With Lenvatinib and Pembrolizumab: A Report of 3 Patients.JCEM case reports · 2025Article
- Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2025Article
- Managing adherence, exposure, and toxicity in oral anticancer therapies.Journal of pharmaceutical health care and sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
introductionSince the first experimentally proven tyrosine kinase inhibitor (TKI) imatinib was introduced in the clinical setting, TKIs have attracted widespread attention because of their remarkable therapeutic effects and improvement of survival rates. TKIs are small-molecule, multi-target, anti-cancer agents that target different tyrosine kinases and block downstream signaling. ADVERSE REACTIONS AND CONCERNS: However, with in-depth research on TKI drugs, the adverse reactions-for example, thyroid dysfunction-have become a concern and thus have attracted the attention of numerous researchers. Thyroid dysfunction, especially hypothyroidism, that occurs in high incidence during TKI therapy has a close relationship with treatment efficacy, but the mechanism of TKI-induced thyroid dysfunction is obscure. DISCUSSION: This review discusses the epidemiology, possible mechanisms, and clinical significance of hypothyroidism in cancer patients treated with TKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.